Zydus FDA Thursday, July 18, 2024 +0.30 Positive

FDA Approves ZITUVIMET XR — Zydus Pharmaceuticals USA Inc.

On July 18, Zydus Pharmaceuticals USA Inc. received FDA approval for the extended-release formulation of sitagliptin and metformin hydrochloride tablets (Brand name ZITUVIMET XR). The approval is anticipated to bolster branded competition and expand oral management options for type 2 diabetes drivers.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed